The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

HeartBeam Inc. (NASDAQ: BEAT)

Investment Considerations HeartBeam has developed and secured FDA clearance for a credit card-sized synthesized 12-Lead ECG device that enables arrhythmia assessment outside of traditional clinical settings. The company’s 12-lead ECG synthesis software successfully met pivotal study endpoints and received FDA 510(k) clearance for arrhythmia assessment in December 2025, enabling initial commercialization. HeartBeam is advancing AI-driven … Continue reading “HeartBeam Inc. (NASDAQ: BEAT)”

View Profile